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Predictors of refractoriness to therapy and healthcare resource
utilization in 378 patients with primary autoimmune hemolytic
anemia from eight Italian reference centers
To the Editor:
Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous
disease with a presentation/phenotype ranging from mild/compen-
sated to life-threatening.1,2 Moreover, some cases show refractoriness
to/relapse after first and further therapy lines, leading to significant
and underestimated healthcare burden. Here, we retrospectively ana-
lyzed 378 primary AIHA cases (135 M and 243 F, median age
61 years, range 5-94) from eight Italian hematological centers and fol-
lowed for a median of 4.3 years (range 1-27) focusing on predictors of
multiple refractoriness to second and further therapy lines and health-
care resource utilization.
Figure 1A shows clinical and laboratory characteristics of AIHA
patients at onset, divided according to the serological type in warm
(direct antiglobulin test-[DAT]-positive for IgG or IgG + C), cold (CAD,
usually IgM driven, DAT-positive for C), mixed (both IgG and high titer
cold agglutinins), and atypical forms (DAT negative, IgA only or warm
IgM). Hemoglobin values were significantly lower and LDH higher in
IgG + C wAIHA, mixed and atypical cases (P < .001 and P = .0034,
respectively), and hemoglobin and LDH values were negatively corre-
lated (P < .001). Absolute reticulocytes were reduced in CAD and
mixed forms (P = .0013), and the reticulocyte index was lower in CAD
(P = .023) and in cases with Hb ≤ 6 g/dL (53 vs 86 P < .001)
(Figure 1B). Overall, inadequate reticulocytosis was observed in more
than half of patients. Second therapy line was mostly administered in
mixed, IgG + C wAIHA, and in CAD (P = .011), and the ultrarefractory
cases requiring four or more lines of therapy were mainly CAD, mixed,
and atypical AIHA. Infections were observed in 14% of cases, mostly
wAIHA and mixed forms (P = .02). Thrombosis occurred in 15%
mostly IgG + C wAIHA and atypical AIHA (P = .04). Evans' syndrome
was more frequent in mixed AIHA and, to a lesser extent, in atypical
(P = .033) and in severe forms (74% with Hb < 8 g/dL vs 26%,
P = .005). Acute renal failure was reported in 3% of patients, with no
relationship with AIHA type/Hb values.
Predictors of relapse/refractoriness were analyzed in a total of
304 relapses, of whom 211 (69%) after first-line, 69 (23%) after
second-line, 19 (6%) after third-line, and 5 (2%) after further therapy
lines. Multivariate Cox regression analysis demonstrated that anemia
severity at onset was associated with an increased risk of relapse, with
the following hazard ratios: 1.98 (95%CI 1.22-3.21) for patients with
Hb ≤ 6 g/dL, 1.74 (95%CI 1.09-2.77) for cases with Hb 6.1-8 g/dL,
and 1.61 (95%CI 0.99-2.62) for those with Hb 8.1-10 g/dL. Even con-
sidering hemoglobin as a continuous variable, each gram of reduction
yielded a 7% greater risk of relapse (95%CI 2-13, P < .013). In addi-
tion, analysis showed increased hazard risks for forms other than
wAIHA (1.21, 95%CI 0.95-1.54), and for Evans association (1.84, 95%
CI 1.24-2.74). Notably, the presentation of an AIHA other than
wAIHA together with Evans syndrome or with Hb < 8 g/dL resulted
in a 2-fold higher risk of relapse; the presence of both Hb < 8 g/dL
and Evans syndrome gave a 3-fold increased risk, and the association
of the three conditions led to a ~4-fold increased risk of multiple
relapses.
Seventy-five patients died during the follow-up, of whom
13 because of AIHA. Overall mortality was higher in more severe
cases (24% for cases with Hb <6 g/dL vs 18% for those with Hb >6 g/
dL, P = .04), with the following hazard risks: Evans syndrome (8, 95%
CI 2.5-26, P = .001), acute renal failure (6.3, 95% CI 1.4-29, P = .016),
and infections (4.8, 95% CI 1.5-15, P = .007). Thrombotic events did
not result in increased risk of death.
Response to treatment is shown in supplementary material. In sum-
mary, ~80% of cases displayed an overall response (OR) after first line
treatment with glucocorticoids, however only 25% had a sustained
response. Rituximab and immunosuppressants were comparably used
in second line (31% and 26%), with better responses for the former
(88% OR, 53% complete responses, CR); immunosuppressants gave
mainly partial responses (PR, 46%) and were generally administered
together with glucocorticoids. Rituximab had a longer relapse free
survival compared with immunosuppressants (22 months, range 2-71
vs 12 months, range 2-43), and a greater proportion of sustained
responses (23/35, 51% vs 13/31, 42%). Splenectomy (n = 38, ~10% of
the whole series) had been performed mostly in second line (63%), par-
ticularly before 2000 (8/9), with very good responses (85%). Regarding
third line therapy, rituximab was preferred compared to immunosup-
pressants (46% vs 15%). Importantly, OR and CR to rituximab were
comparable to those observed in second line (92% and 41%). Splenec-
tomy had become a third line option in most recent years (11/24, 46%)
and confirmed its excellent performance. Further lines were required in
29 multirefractory patients (8% of cases), and included glucocorticoids/
rituximab, glucocorticoids/immunosuppressants, regular transfusions,
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FIGURE 1 (A) Clinical and laboratory characteristics of patients at onset, therapy lines, complications and death, divided according to AIHA
serological type. (B) Reticulocyte counts as a function of Hb at onset: AIHA cases are grouped in mild (Hb > 10 g/dL), moderate (Hb 8.1-10 g/dL),
severe (Hb 6.1-8 g/dL), and very severe (Hb ≤ 6 g/dL) (left). Individual values of Hb are shown in relation to reticulocyte index (absolute
reticulocyte count × patient’ Hb/normal Hb), with the corresponding equation line (ret(× 1000) = 119 + 29.2 × Hb - 2.4 × Hb2) (right). Both
panels A and B indicate that compensatory reticulocytosis increases until Hb values of about 8 g/dL, but more severe cases are characterized by
reticulocytopenia/inadequate reticulocytosis. (C) Healthcare resource utilization: Percentage of patients receiving transfusions, highly expensive
drugs (rituximab, bortezomib, eculizumab), and splenectomized, grouped according to AIHA serological type
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bortezomib (1.3 mg/m2 iv single agent on days 1, 4, 8, 11, n = 8),
plasma-exchange (N = 5), eculizumab (N = 2), erythropoietin (N = 12),
high dose cyclophosphamyde/vincristine (N = 1), and autologous
peripheral stem cell transplant (N = 1). Response to treatments is diffi-
cult to assess, due to their combinations/overlap. Notably, six cases
underwent splenectomy as forth or further line, all obtaining a
response. Considering all the 32 cases that respond to splenectomy
(either performed in second, third, or further lines), 13 (41%) relapsed
after a median of 16 months (range 2-147), while 19 (59%) cases are
still on remission at the time of the study. Regarding response to treat-
ment according to AIHA type, a CR to glucocorticoids was mostly
observed in wAIHA, mixed and atypical cases (~50%), whereas CR rate
was lower in CAD (24%) (P = .0015), and generally observed at high
dosages. A complete response to rituximab was mainly observed in IgG
wAIHA (62%), whereas the drug was less effective in IgG + C wAIHA,
CAD, and mixed forms (44%-54%).
Figure 1C and Supporting Information show healthcare utiliza-
tion in a subgroup of 190 cases comparable to the remaining 188 in
terms of demographics, hematological parameters, number, and type
of therapy lines. One hundred twenty-one patients (64%) required at
least one hospital admission, with 9% needing three or more. The
median admission duration was 15 days, with 13% of cases needing
more than 30 days, and admissions length was negatively correlated
to Hb levels (r = −0.26, P < .001). The higher frequency was
observed in IgG + C wAIHA, mixed and atypical cases (P = .006).
Concerning outpatients, median number of visits per year was five,
but 42 cases (22%) required more than a monthly visit. As regards
therapeutic procedures, 103 patients (54%) required at least one
transfusion, with 11/103 patients (11%) needing more than 20 trans-
fusions (the established threshold for chelation), and six cases more
than 50. Transfusion need was higher in IgG + C wAIHA, mixed and
atypical cases (P = .004), and correlated with a more severe disease,
that is, anemia, hemolysis and inadequate bone marrow compensa-
tion (Hb r = −.26, P < .001; LDH r = .21, P < .01; BMRI r = .15,
P < .05). Considering transfusions as a function of follow-up length,
the median was 2 per year, with 27 cases necessitating 4 or more
(one subject about a weekly support). Highly expensive drugs were
administered in 65 cases (34%, 56 rituximab, 8 bortezomib, and
2 eculizumab), and splenectomy performed in 20 patients (11%). The
administration of highly expensive drugs was higher in CAD and
mixed cases (P = .01).
In conclusion, this is the largest study aimed at identifying predic-
tors of refractoriness to multiple therapy lines and healthcare resource
utilization in primary AIHA in the real-life and outside clinical trials.
We found that hemoglobin level at onset is the only laboratory param-
eter associated with an increased risk of refractoriness, from 2-fold
for moderate to 3-fold for severe cases. Anemia severity was associ-
ated with reticulocytopenia/inadequate reticulocytosis, present in
more than a half of patients, typically CAD and mixed forms. Throm-
bocytopenia (Evans syndrome) resulted in a 2-fold increased relapse
risk, highlighting the detrimental effect of a more complex immune
dysregulation involving multiple hematological lineages. Moreover,
refractory/relapsing AIHAs were those with complement involvement
(warm IgG + C, mixed, and CAD), suggesting the primary role of this
powerful amplification system in the degree of AIHA immune
dysregulation. Regarding therapy, known to be mainly based on
experts opinion,3–5 rituximab had a longer relapse free survival
(~2 years), and was effective in ~50% of cases in first and further lines.
The drug was used as first or early-second line in very severe cases,
particularly in CAD cases that are known to respond to unacceptable
high glucocorticoid doses only. At variance, immunosuppressants
induced partial responses with decreasing efficacy after first line. Sple-
nectomy had high response rates (~85%) and was curative in ~60% of
warm AIHA cases, even when performed as third or further lines. This
option, although marked by infectious and thrombotic complications,
and contraindicated in CAD, should not be forgotten, given its poten-
tial curative ability, as recently suggested for immune thrombocytope-
nia.6 Healthcare resource utilization was important in AIHA, with
~2/3 of patients requiring hospital admissions, 1/2 transfusions, and
~1/3 highly expensive drugs. In a small group of severe/ultrarefrac-
tory cases (10%-15%, mainly CAD, IgG + C wAIHA, mixed and atypi-
cal forms) admissions lasted more than 30 days, transfusion need
exceeded 20 units per year, the established threshold for chelation,
and several highly expensive drugs were administered, representing a
significant burden on the patient and the medical system.
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